Search clinical trials for: SHR7390

Total 52 results

The Affiliated Hospital of Qingdao University

Completed

A Phase I Clinical Study on SHR6390 in Healthy Chinese Volunteers

Healthy Volunteers

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Phase I Study of SHR7390 in Patients With Advanced Solid Tumors

Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study to Investigate Relative Bioavailability of Different Formulations of SHR6390 in Healthy Subjects

Healthy Volunteers

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Completed

SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study to Evaluate the Mass Babance and Biotransformation of [14C]SHR6390 in Healthy Adult Male Volunteers

Healthy Adult Male Volunteers

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR6390 in Advanced Solid Tumor Patients

Neoplasm

China
Jiangsu HengRui Medicine Co., Ltd.
Peking University Cancer Hospital & Institute

Unknown

A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients

Melanoma

China
Atridia Pty Ltd.

Completed

A Trial of SHR6390 in Healthy Caucasian Volunteers

Healthy Volunteers

Australia
Peking University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Gastric Cancer

Gastric Cancer

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer (DAP-Her-01)

Metastatic Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of SHR6390 in Renal Insufficiency and Healthy Subjects

Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer

ER+ / HER2- Advanced Breast Cancer

China
Tianjin Medical University Cancer Institute and...
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.

Advanced Breast Cancer | Metastatic Breast Cancer

China
Beijing 302 Hospital

Not yet recruiting

Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study

HR+/HER2- Advanced Breast Cancer

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer

ER-Positive, HER2-Negative Breast Cancer

China
Harbin Medical University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC

HCC | NSCLC | CRC
Jiangsu HengRui Medicine Co., Ltd.

Unknown

An Investigational Study of SHR6390 in Participants With Mild to Moderate Liver Impairment and Healthy Participants

Hepatic Impairment | Healthy Participants
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Clinical Study Evaluating the Relative Bioavailability of SHR7280 Dry Suspension and Tablets

Endometriosis, Uterine Fibroids, Male Hormone-sensitive Prostate Cancer, Assisted Reproduction

China
Jiangsu HengRui Medicine Co., Ltd.

Enrolling by invitation

Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative

Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer

China
Tianjin Medical University Cancer Institute and...
Jiangsu HengRui Medicine Co., Ltd.

Completed

SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer.

Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Identify Effective Doses of SHR7280 Tablets in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART)

Female Subjects Undergoing COH in ART to Prevent Early Ovulation

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer

Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer

Hormone Sensitive Prostate Cancer

China
Fudan University

Recruiting

Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer (MULAN)

Breast Cancer | Metastatic Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

The Pharmacokinetic(PK)/Pharmacodynamics(PD) Study of SHR7280 Tablets in Premenopausal Subjects With Endometriosis.

Endometriosis

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

The PK/PD Study of SHR7280 Tablets in Healthy Subjects.

Healthy Subjects

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase II/III Study of Efficacy and Safety of SHR7280 Tablets in Subjects With Menorrhagia With Uterine Fibroids

Uterine Fibroids With Menorrhagia

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

To Compare the Efficacy and Safety of Oral SHR 7280 Tablets With Ganirelix Acetate Injection in Infertile Female Subjects

Infertile Female Subjects Undergoing Controlled Ovarian Hyperstimulation to Suppress Premature LH Surge and Prevent Early Ovulation

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Effect of Omeprazole on the Pharmacokinetics of SHR6390 in Healthy Subjects

Advanced Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors

Solid Tumor

China
Shengjing Hospital
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment

Breast Cancer

China
Henan Cancer Hospital

Active, not recruiting

Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Metastatic Breast Cancer

China
Fudan University
Chongqing University Cancer Hospital; Sun Yat-sen University; Peking University... and other collaborators

Recruiting

Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02

Breast Cancer | Metastatic Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Advanced Breast Cancer

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy

Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Effect of Rifampicin on the Pharmacokinetics of SHR6390 in Healthy Subjects

Healthy Subjects

China
Shengjing Hospital

Active, not recruiting

Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial

Breast Cancer

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)

Breast Neoplasms

China
Ruijin Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.

Breast Cancer | HER2-positive Breast Cancer | ER-positive Breast Cancer
Jinming Yu
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer (INPHASE)

Metastatic Breast Cancer | HER2-positive Breast Cancer

China
Ruijin Hospital

Not yet recruiting

SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic Cancer

Pancreatic Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Advanced Breast Cancer

China
Fudan University
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer (PLEASURABLE)

Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Effect of Itraconazole on the Pharmacokinetics of SHR6390 in Healthy Subjects

Healthy Subjects

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Advanced Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Drug-drug Interaction Study of SHR6390 on Healthy Chinese Volunteers

Advanced Solid Tumor

China
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

mFOLFOX6 Combined With Dalpiciclib in Patients With Metastatic Colorectal Cancer (FIND)

Advanced/Metastatic Colorectal Cancer

China
Fudan University

Recruiting

Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer (BCTOP-L-M01)

Breast Cancer | Advanced Breast Cancer

China
Hebei Medical University Fourth Hospital

Recruiting

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

Breast Cancer

China
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory Plasma Cell Myeloma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Non-Hodgkin Lymphoma | Refractory Histiocytic and Dendritic Cell Neoplasm | Refractory Non-Hodgkin Lymphoma | Recurrent Plasma Cell Myeloma

United States

3

Subscribe